Mintu Turakhia, M.D.
Division of Cardiology & Cardiac Electrophysiology
University of California, San Francisco School of Medicine

"In conclusion, there is now a large body of evidence to support the added prognostic value, clinical benefit, and cost-effectiveness of MTWA testing. A negative MTWA offers strong negative predictive value in assuring a 3% or less risk of SCD. CMS has come forth strongly in favor of use of the technology and reimbursement and a handful of private insurance companies have followed suit. Whether MTWA testing will someday be mandatory remains to be seen, but the technology is clearly here to stay."

http://www.medcompare.com/spotlight.asp?...